Scientific publications
The publications presented here are a thematic selection of the scientific work carried out in the main research areas of the department.
They are arranged by research line, so as to show the continuity of the work, from descriptive studies and cohorts through to therapeutic trials, translational studies, recommendations and collaborative work.
For each reference are given, where relevant, the type of study, the year of publication and the link to the article or its bibliographic identifier. Manuscripts available as a preprint only are explicitly labelled as such and are not presented as peer-reviewed publications.
On 8 September 2026, Europe PMC indexed 497 references for the author query “Mekinian A”. The selection presented on this page keeps 38 of them, chosen to represent the different research lines and the main scientific contributions.
This selection is not meant to be an exhaustive bibliography. The complete and up-to-date lists are available through PubMed and ORCID, in the right-hand column.
Notable publications
- Mekinian A, et al. American College of Rheumatology Guidance Statement for Diagnosis and Management of VEXAS Developed by the International VEXAS Working Group Expert Panel. Arthritis & Rheumatology, 2026;78(3):509-522. DOI 10.1002/art.43287 · PMID 40787890 · first authorcited 15 times
- Hydroxychloroquine in recurrent pregnancy loss: data from a French prospective multicenter registry. Human Reproduction, 2024;39(9):1934-1941. DOI 10.1093/humrep/deae146 · PMID 38942601 · FALCO registry · last authorcited 11 times
- Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial. Annals of the Rheumatic Diseases, 2019. DOI 10.1136/annrheumdis-2018-214229cited 333 times
- Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia. Rheumatology (Oxford), 2016. DOI 10.1093/rheumatology/kev294 · MINHEMON networkcited 176 times
- Long-Term Outcomes and Prognostic Factors of Complications in Takayasu Arteritis: A Multicenter Study of 318 Patients. Circulation, 2017. DOI 10.1161/circulationaha.116.027094cited 176 times
- Mekinian A, et al. Low-dose interleukin-2 for recurrent early pregnancy loss: a proof-of-concept study (FaCIL-2 trial). medRxiv preprint, 2025. preprint: results not yet peer-reviewed
- Abisror N, et al. Successful live birth following immunomodulatory therapy in a patient with multiple recurrent pregnancy loss and massive perivillous fibrinoid deposition. Journal of Reproductive Immunology, 2026;176:104931. DOI 10.1016/j.jri.2026.104931 · PMID 42392016 · last author
By research area
Reproductive immunology
- Unexplained Recurrent Miscarriage and Recurrent Implantation Failure: Is There a Place for Immunomodulation? Am J Reprod Immunol, 2016. DOI 10.1111/aji.12493cited 117 times
- The Endometrial Immune Profiling May Positively Affect the Management of Recurrent Pregnancy Loss Front Immunol, 2021. DOI 10.3389/fimmu.2021.656701cited 24 times
Recurrent early pregnancy loss
- Proportion of Cytotoxic Peripheral Blood Natural Killer Cells and T-Cell Large Granular Lymphocytes in Recurrent Miscarriage and Repeated Implantation Failure: Case-Control Study and Meta-analysis Arch Immunol Ther Exp (Warsz), 2019. DOI 10.1007/s00005-019-00546-5cited 24 times
Recurrent implantation failure
- Intralipid therapy for unexplained recurrent miscarriage and implantation failure: Case-series and literature review Eur J Obstet Gynecol Reprod Biol, 2020. DOI 10.1016/j.ejogrb.2020.06.017cited 19 times
Inflammatory placental disease
- Chronic histiocytic intervillositis: outcome, associated diseases and treatment in a multicenter prospective study Autoimmunity, 2015. DOI 10.3109/08916934.2014.939267cited 60 times
- Chronic Villitis of unknown etiology (VUE): Obstetrical features, outcome and treatment J Reprod Immunol, 2021. DOI 10.1016/j.jri.2021.103438cited 25 times
- Antiphospholipid syndrome and other autoimmune diseases associated with chronic intervillositis Arch Gynecol Obstet, 2015. DOI 10.1007/s00404-014-3536-6cited 21 times
Antiphospholipid syndrome
- The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 1000 consecutive cases Autoimmun Rev, 2019. DOI 10.1016/j.autrev.2018.12.006cited 92 times
- Treatment strategies and pregnancy outcomes in antiphospholipid syndrome patients with thrombosis and triple antiphospholipid positivity. A European multicentre retrospective study Thromb Haemost, 2014. DOI 10.1160/th14-03-0191cited 84 times
- Effect of Additional Treatments Combined with Conventional Therapies in Pregnant Patients with High-Risk Antiphospholipid Syndrome: A Multicentre Study Thromb Haemost, 2018. DOI 10.1055/s-0038-1632388cited 70 times
Pregnancy and autoimmune diseases
- Evaluation of lupus anticoagulant, damage, and remission as predictors of pregnancy complications in systemic lupus erythematosus: the French GR2 study Rheumatology (Oxford), 2022. DOI 10.1093/rheumatology/keab943cited 35 times
- European registry of babies born to mothers with antiphospholipid syndrome Ann Rheum Dis, 2013. DOI 10.1136/annrheumdis-2011-201167cited 60 times
VEXAS syndrome
- Further characterization of clinical and laboratory features in VEXAS syndrome: large-scale analysis of a multicentre case series of 116 French patients Br J Dermatol, 2022. DOI 10.1111/bjd.20805cited 333 times
- Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study Blood, 2022. DOI 10.1182/blood.2022016642cited 163 times
- Azacitidine for patients with Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry Br J Haematol, 2022. DOI 10.1111/bjh.17893cited 125 times
- Pleuropulmonary Manifestations of Vacuoles, E1 Enzyme, X-Linked, Autoinflammatory, Somatic (VEXAS) Syndrome Chest, 2023. DOI 10.1016/j.chest.2022.10.011cited 47 times
Autoinflammatory diseases and AA amyloidosis
- Prognosis assessment of cardiac involvement in systemic AL amyloidosis by magnetic resonance imaging Am J Med, 2010. DOI 10.1016/j.amjmed.2010.03.022cited 49 times
- 18F-FDG PET/CT in patients with amyloid light-chain amyloidosis: case-series and literature review Amyloid, 2012. DOI 10.3109/13506129.2012.682833cited 45 times
Systemic autoimmune diseases
- Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial Ann Rheum Dis, 2021. DOI 10.1136/annrheumdis-2020-218467cited 85 times
- International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus Autoimmun Rev, 2017. DOI 10.1016/j.autrev.2017.04.011cited 25 times
Cogan's syndrome
- French protocol for diagnosis and management of Cogan's syndrome La Revue de médecine interne, 2025. DOI 10.1016/j.revmed.2024.09.007
- Cogan's syndrome. A comprehensive review European Journal of Internal Medicine, 2025. DOI 10.1016/j.ejim.2025.05.007
- Syndrome de Cogan La Revue de médecine interne, 2021. DOI 10.1016/j.revmed.2020.07.007
- Cogan syndrome: Characteristics, outcome and treatment in a French nationwide retrospective study and literature review Autoimmunity Reviews, 2017. DOI 10.1016/j.autrev.2017.10.005
Large-vessel vasculitis
- Long-Term Outcomes and Prognostic Factors of Complications in Takayasu Arteritis: A Multicenter Study of 318 Patients Circulation, 2017. DOI 10.1161/circulationaha.116.027094cited 176 times
- Efficacy of Biological-Targeted Treatments in Takayasu Arteritis: Multicenter, Retrospective Study of 49 Patients Circulation, 2015. DOI 10.1161/circulationaha.114.014321cited 125 times
- Management of large-vessel vasculitis with FDG-PET: a systematic literature review and meta-analysis Medicine (Baltimore), 2015. DOI 10.1097/md.0000000000000622cited 193 times
Systemic sclerosis
- Survival and prognosis factors in systemic sclerosis: data of a French multicenter cohort, systematic review, and meta-analysis of the literature Arthritis Res Ther, 2019. DOI 10.1186/s13075-019-1867-1cited 143 times
- Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: the placebo-controlled SEDUCE study Ann Rheum Dis, 2016. DOI 10.1136/annrheumdis-2014-207001cited 111 times
- Circulating follicular helper T cells are increased in systemic sclerosis and promote plasmablast differentiation through the IL-21 pathway which can be inhibited by ruxolitinib Ann Rheum Dis, 2019. DOI 10.1136/annrheumdis-2018-214382cited 82 times
Myeloid disorders and inflammatory manifestations
- Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study Rheumatology (Oxford), 2016. DOI 10.1093/rheumatology/kev294cited 176 times
- Efficacy of Azacitidine in autoimmune and inflammatory disorders associated with myelodysplastic syndromes and chronic myelomonocytic leukemia Leuk Res, 2016. DOI 10.1016/j.leukres.2016.02.005cited 95 times
- Autoimmune manifestations associated with myelodysplastic syndromes Ann Hematol, 2018. DOI 10.1007/s00277-018-3472-9cited 69 times
- Erdheim-Chester disease associated with chronic myelomonocytic leukemia harboring the same clonal mutation Haematologica, 2019. DOI 10.3324/haematol.2019.223552cited 22 times
Immunomodulatory treatments
- Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial Ann Rheum Dis, 2019. DOI 10.1136/annrheumdis-2018-214229cited 333 times
- The universal effects of low-dose interleukin-2 across 13 autoimmune diseases in a basket clinical trial J Autoimmun, 2024. DOI 10.1016/j.jaut.2024.103172cited 33 times
- A Phase II prospective trial of azacitidine in steroid-dependent or refractory systemic autoimmune/inflammatory disorders and VEXAS syndrome associated with MDS and CMML Leukemia, 2022. DOI 10.1038/s41375-022-01698-8cited 78 times